Pharmacokinetic evaluation of ambrisentan

Bibliography

• Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008;51:527-38
   Web of Science ®Google Scholar
• Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36
   PubMed Web of Science ®Google Scholar
• D'Alonzo GE, Barst RJ, Ayres SM, Survival in patients with primary pulmonary hypertension. Ann Intern Med 1991;115:343-9
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Markevych I, Spiekerkoetter E, Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26:858-63
   PubMed Web of Science ®Google Scholar
• Humbert M, Morrell NW, Archer SL, Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):13S-24S
   PubMed Web of Science ®Google Scholar
• Barst RJ, Gibbs JS, Ghofrani HA, Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:78-84
   PubMed Web of Science ®Google Scholar
• Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur J Respir J 2008;31:407-15
   PubMed Web of Science ®Google Scholar
• Langleben D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin Chest Med 2007;28:117-25
   PubMed Web of Science ®Google Scholar
• Traiger GL. Pulmonary arterial hypertension. Crit Care Nurs Q 2007;30:20-41
   PubMedGoogle Scholar
• Kirkby NS, Hadoke PWF, Bagnall AJ, Webb DJ. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 2008;153:1105-19
   PubMed Web of Science ®Google Scholar
• Raja SG. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Curr Opin Investig Drug 2010;11:1066-73
   PubMed Web of Science ®Google Scholar
• Gabbay E, Fraser J, McNeil K. Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag 2007;3:887-900
   PubMedGoogle Scholar
• Badesch DB, Abman SH, Simonnequ G, Medical therapy of pulmonary arterial hypertension. Chest 2007;131:1917-28
   PubMed Web of Science ®Google Scholar
• Chanick RN, Simmoneau G, Sitbon O, Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001;358:1119-23
   PubMed Web of Science ®Google Scholar
• Rubin, LJ, Badesch DB, Barst RJ, Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903
   PubMed Web of Science ®Google Scholar
• Galie N, Rubin LJ, Hoeper MM, Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet 2008;371:2093-100
   PubMed Web of Science ®Google Scholar
• Galie N, Beghetti M, Gatzoulis MA, Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54
   PubMed Web of Science ®Google Scholar
• Keogh AM, McNeil KD, Wlodarczyk J, Quality of life in pulmonary arterial hypertension: improved and maintained with bosentan. J Heart Lung Transplantation 2007;26:181-7
   PubMed Web of Science ®Google Scholar
• Barst RJ, Langleben D, Frost A, Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7
   PubMed Web of Science ®Google Scholar
• Barst RJ, Langleben D, Badesch D, Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-56
   PubMed Web of Science ®Google Scholar
• Benza RL, Barst RJ, Galie N, Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome an survival. Chest 2008;134:775-82
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Oudiz RJ, Frost A, Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Eur Respir J 2005;25:244-9
   PubMed Web of Science ®Google Scholar
• Liu C, Chen J, Gao Y, Endothelin receptor antagonists in pulmonary arterial hypertension. Cochrane Database Syst Rev 2009;3:CD004434
   Google Scholar
• Casserly B, Klinger JR. Ambrisentan for the treatment of pulmonary arterial hypertension. Drug Des Dev Ther 2008;2:265-80
   Google Scholar
• Galie N, Badesch D, Oudiz R, Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529-35
   PubMed Web of Science ®Google Scholar
• Galie N, Olschewski H, Oudiz RJ, Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-19
   PubMed Web of Science ®Google Scholar
• Oudiz RJ, Galie N, Olschewski H, Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:1971-81
   PubMed Web of Science ®Google Scholar
• Blalock SE, Matulevicius S, Mitchell LC, Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. J Card Fail 2010;16:121-7
   PubMed Web of Science ®Google Scholar
• McGoon MD, Frost AE, Oudiz RJ, Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009;135:122-9
   PubMed Web of Science ®Google Scholar
• Cartin-ceba R, Swanson K, Iyer V, Safety and efficacy of ambrisentan for the therapy of portopulmonary hypertension. Chest 2010. [Epub ahead of print]
   Google Scholar
• Letairis (ambrisentan) package insert. Gilead Sciences, Inc., Foster City, CA; 2009 Aug. Accessed October 2010
   Google Scholar
• Rubin LJ, Dufton C, Gerber MJ. Ambrisentan for pulmonary arterial hypertension. Future Cardiol 2005;1:1-8
   PubMedGoogle Scholar
• Price LC, Howard LS. Endothelin receptor antagonists in pulmonary arterial hypertension: rational and place in therapy. Am J Cardiovasc Drugs 2008;8:171-85
   PubMed Web of Science ®Google Scholar
• Walker G, Mandagere A, Dufton C, Venitz J. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers. Br J Clin Pharmacol 2009;67:527-34
   PubMed Web of Science ®Google Scholar
• Spence R, Mandagere A, Dufton C, Venitz J. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. J Clin Pharmcol 2008;48:1451-9
   PubMed Web of Science ®Google Scholar
• Richards DB, Walker GA, Mandagere A, Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. J Clin Pharmacol 2009;49:719-24
   PubMed Web of Science ®Google Scholar
• Spence R, Mandagere A, Walker G, Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: an open-label, single-sequence, single-centre study. Clin Drug Investig 2010;30:313-24
   PubMed Web of Science ®Google Scholar
• Croxtall JD, Keam SJ. Ambrisentan. Drugs 2008;68:2195-204
   PubMed Web of Science ®Google Scholar
• Hoeper MM. Drug therapy of pulmonary arterial hypertension: current and future agents. Drugs 2005;65:1337-54
   PubMed Web of Science ®Google Scholar
• Croom KR, Curran MP. Sildenafil: a review of its use in pulmonary arterial hypertension. Drugs 2008;68:383-97
   PubMed Web of Science ®Google Scholar
• Galie N, Ghofrani HA, Torbicki A, Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57
   PubMed Web of Science ®Google Scholar
• Simonneau G, Rubin LJ, Galie N, Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521-30
   PubMed Web of Science ®Google Scholar
• Effects of the combination of bosentan and sildenafil versus sildenafil monotherapy on pulmonary arterial hypertension (PAH) (Compass 2). Available from: www.clinicaltrials.gov/ct2/show/NCT00303459?term=bosentan&rank=9 [Last accessed 15 October 2010]
   Google Scholar
• Simonneau G, Robbins IM, Geghetti M, Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-54
   PubMed Web of Science ®Google Scholar
• Kawut SM. Caring for the orphan's orphan: treatment of patients with portopulmonary hypertension. Eur Respir J 2007;30:1038-40
   PubMed Web of Science ®Google Scholar
• Schulze-Neick I, Gilbert N, Ewert R, Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Am Heart J 2005;150:716
   PubMedGoogle Scholar
• Ivy DD. Pharmacokinetics and safety of ambrisentan in pediatric patients with pulmonary arterial hypertension. Platform presentation at the American Thoracic Society International Conference, San Diego, CA; 2009
   Google Scholar
• Humbert M, Barst RJ, Robbins IM, Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATH-2. Eur Respir J 2004;24:353-9
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Oudiz RJ, Frost A, Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257-63
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Leuchte H, Halank M, Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691-4
   PubMed Web of Science ®Google Scholar
• Red Book 2010: Pharmacy's Fundamental Reference, 2010 edition. Thomson Reuters, Montvale (NJ); 2010
   Google Scholar
• A study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH) (AMBITION). Available from: www.clinicaltrials.gov/ct2/show/NCT01178073?term=ambition+study&rank=1 [Last accessed 15 October 2010]
   Google Scholar
• Tracleer (bosentan) package insert. Actelion Pharmaceuticals US, Inc., South San Francisco, CA; 2009 Aug. Accessed October 2010
   Google Scholar
• Thelin (sitaxsentan) package insert. Pfizer Canada, Kirkland, Quebec, Canada; 2008 Nov. Accessed October 2010
   Google Scholar